Cytokine-armed vaccinia virus infects the mesothelioma tumor microenvironment to overcome immune tolerance and mediate tumor resolution

Cancer Gene Therapy

Volumn 17, Issue 6, 2010, Pages 429-440

  Jackaman, C ^a,b   Nelson, D J ^a,b,c,d  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Western Australia Biomedical Research Institute   (Australia)

^d CURTIN UNIVERSITY   (Australia)

Author keywords

Cytokines; Dendritic cells; Macrophages; Mesothelioma; Tumor immunity; Viral vectors

Indexed keywords

CYTOKINE; INTERLEUKIN 12; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; FOWLPOX VIRUS; GENE CONSTRUCT; GENE EXPRESSION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MESOTHELIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; VACCINIA VIRUS; VIRUS EXPRESSION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; FOWLPOX VIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; INTERLEUKIN-2; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, INBRED C57BL; T-LYMPHOCYTES; TUMOR BURDEN; VACCINIA VIRUS;

FOWLPOX VIRUS; MURINAE; VACCINIA VIRUS;

EID: 77952506762     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.85     Document Type: Article

References (51)

1. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA. Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 1995; 2: 151-159.
2. Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, Hodge JW, Schlom J, Sabzevari H. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004; 11: 665-680.
3. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006; 146: 344-353.
4. Kudo-Saito C, Garnett CT, Wansley EK, Schlom J, Hodge JW. Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity. Cancer Immunol Immunother 2007; 56: 1897-1910.
5. Robinson BW, Mukherjee SA, Davidson A, Morey S, Musk AW, Ramshaw I et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 1998; 21: 211-217.
6. Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res 2006; 16: 182-188.
7. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101(Suppl 2): 14567-14571.
8. Wu Q, Moyana T, Xiang J. Cancer gene therapy by adenovirus-mediated gene transfer. Curr Gene Ther 2001; 1: 101-122.
9. Schambach A, Baum C. Clinical application of lentiviral vectors\concepts and practice. Curr Gene Ther 2008; 8: 474-482.
10. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br J Pharmacol 2009; 157: 153-165.
11. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M. Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 2008; 8: 66-78.
12. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663-670.
13. Mukherjee S, Upham JW, Ramshaw I, Bundell C, van Bruggen I, Robinson BW et al. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine IL-12. Cancer Gene Ther 2003; 10: 591-602.
14. Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15: 1361-1371.
15. Mastrangelo MJ, Maguire Jr HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-422.
16. Peplinski GR, Tsung K, Meko JB, Norton JA. In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta. Surgery 1995; 118: 185-190; discussion 190-191.
17. Flanagan K, Glover RT, Horig H, Yang W, Kaufman HL. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine 2004; 22: 2894-2903.
18. Yang AS, Monken CE, Lattime EC. Intratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immuno-logical ignorance to tumor antigen. Cancer Res 2003; 63: 6956-6961.
19. Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 1996; 23: 88-100.
20. Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H et al. Intratumoral injection of IL-12 plasmid DNA\results of a phase I/IB clinical trial. Cancer Gene Ther 2007; 14: 717-723.
21. Liu Y, Huang H, Saxena A, Xiang J. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, syner-gizes to facilitate regression of established tumors. Cancer Gene Ther 2002; 9: 533-542.
22. Rochlitz C, Dreno B, Jantscheff P, Cavalli F, Squiban P, Acres B et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 2002; 9: 289-295.
23. Gambotto A, Tuting T, McVey DL, Kovesdi I, Tahara H, Lotze MT et al. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Ther 1999; 6: 45-53.
24. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 1994; 68: 8125-8130.
25. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin Cancer Res 2000; 6: 24-33.
26. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 2005; 11: 3017-3024.
27. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178(4 Pt 1): 1515-1520.
28. Jolly D. Viral vector systems for gene therapy. Cancer Gene Ther 1994; 1: 51-64.
29. Meko JB, Tsung K, Norton JA. Cytokine production and antitumor effect of a nonreplicating, noncytopathic recom-binant vaccinia virus expressing interleukin-12. Surgery 1996; 120: 274-282; discussion 282-283.
30. Ramshaw I, Ruby J, Ramsay A, Ada G, Karupiah G. Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo. Immunol Rev 1992; 127: 157-182.
31. Mackett M, Smith GL, Moss B. General method for production and selection of infectious vaccinia virus recom-binants expressing foreign genes. J Virol 1984; 49: 857-864.
32. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987; 329: 545-546.
33. Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998; 83: 2099-2104. (Pubitemid 28525391)
34. Boutin C, Schlesser M, Frenay C, Astoul P. Malignant pleural mesothelioma. Eur Respir J 1998; 12: 972-981.
35. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 2003; 171: 5051-5063.
36. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BW, Scott B. Cytokine gene therapy of mesothe-lioma. Immune and antitumor effects of transfected inter-leukin-12. Am J Respir Cell Mol Biol 1999; 21: 347-356.
37. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BW. Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19: 738-746.
38. Boyle DB, Coupar BE. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res 1988; 10: 343-356.
39. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
40. Weston L, Geczy A, Farrell C. A convenient and reliable IL-2 bioassay using frozen CTLL-2 to improve the detection of helper T lymphocyte precursors. Immunol Cell Biol 1998; 76: 190-192.
41. Jackaman C, Cornwall S, Lew AM, Zhan Y, Robinson BW, Nelson DJ. Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells. Eur Respir J 2009; 34: 162-175.
42. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L et al. Activation of tumor-associated macro-phages by the vascular disrupting agent 5,6-dimethylxan-thenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005; 65: 11752-11761.
43. Hegmans JP, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006; 27: 1086-1095.
44. Wali A, Strayer DS. Infection with vaccinia virus alters regulation of cell cycle progression. DNA Cell Biol 1999; 18: 837-843.
45. Cheers C, Janas M, Ramsay A, Ramshaw I. Use of recombinant viruses to deliver cytokines influencing the course of experimental bacterial infection. Immunol Cell Biol 1999; 77: 324-330.
46. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999; 163: 6762-6768.
47. Drillien R, Spehner D, Bohbot A, Hanau D. Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology 2000; 268: 471-481.
48. Deng L, Dai P, Ding W, Granstein RD, Shuman S. Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J Virol 2006; 80: 9977-9987.
49. Yao Y, Li P, Singh P, Thiele AT, Wilkes DS, Renukaradhya GJ et al. Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol 2007; 246: 92-102.
50. Di Nicola M, Napoli S, Anichini A, Mortarini R, Romagnoli L, Magni M et al. Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by stauros-porine or vaccinia virus infection. Haematologica 2003; 88: 1396-1404.
51. Mathew A, Ennis FA, Rothman AL. Transient decreases in human T cell proliferative responses following vaccinia immunization. Clin Immunol 2000; 96: 100-107.